Endovascular treatment for medium or distal vessel occlusion stroke (DISTAL): 12-month outcomes of a multicentre, open-label, randomised trial

BACKGROUND: Long-term evidence for endovascular treatment in medium or distal vessel occlusion stroke is scarce. Three out of four randomised trials reported no benefit of endovascular treatment over best medical treatment at 90 days. We aimed to assess efficacy of endovascular treatment plus best medical treatment versus best medical treatment alone at 12 months in patients enrolled in the DISTAL trial, as well as overall survival. METHODS: DISTAL was an open-label, randomised trial with blinded endpoint assessment conducted at 55 hospitals in Europe and the Middle East. Adults (≥18 years) with acute ischaemic stroke due to medium or distal vessel occlusion (occlusion of co-dominant or non-dominant M2 or M3-M4 middle cerebral artery, A1-A3 anterior cerebral artery, or P1-P3 posterior cerebral artery) presenting from home within 6 h of last known well, or between 6 h and 24 h if neuroimaging demonstrated potentially salvageable tissue, were randomly assigned (1:1) through a centralised web-based system to endovascular treatment plus best medical treatment or best medical treatment alone. The prespecified primary outcome at 12 months was disability measured by use of the ordinal modified Rankin Scale (mRS; scores 5 and 6 combined) in the intention-to-treat population. The only safety outcome was overall survival. The trial is registered on ClinicalTrials.gov (NCT05029414) and is completed. FINDINGS: Between Dec 16, 2021, and July 10, 2024, we enrolled 553 patients. Ten patients declined post-hoc consent, leaving 543 participants in the analysis (239 [44%] females and 304 [56%] males; median age 77 years, IQR 68-84). 271 (50%) were assigned to endovascular treatment plus best medical treatment and 272 (50%) to best medical treatment alone. The median NIHSS score at admission was 6 (IQR 5-9); 355 (65%) participants received intravenous thrombolysis. Predominant occlusion locations were the M2 (239 [44%]), M3 (146 [27%]), P2 (73 [13%]), and P1 (30 [6%]) segments. 12-month data were available for 524 (97%) participants. The median mRS score was 2 (IQR 1-4) in the endovascular treatment plus best medical treatment group and 2 (1-4) in the best medical treatment alone group. There was no difference in 12-month mRS distribution between endovascular treatment plus best medical treatment and best medical treatment alone (adjusted common odds ratio for better functional outcome 0·81, 95% CI 0·59-1·12; p=0·20). Overall survival was similar between the two groups (hazard ratio 1·46, 95% CI 0·93-2·30; p=0·10). INTERPRETATION: In patients with a medium or distal vessel occlusion stroke, endovascular treatment plus best medical treatment was not associated with a reduction of disability or death at 12 months compared with best medical treatment. These results are consistent with the 90-day results. Routine endovascular treatment is therefore not supported for patients with mild-to-moderate medium or distal vessel occlusion stroke. FUNDING: Swiss National Science Foundation, Gottfried und Julia Bangerter-Rhyner-Foundation, Medtronic, Stryker Neurovascular, Phenox, Rapid Medical, and Penumbra.

Authors

Institutions

Publication Details

Journal
The Lancet Neurology
Published
2026-05-01
DOI
https://doi.org/10.1016/s1474-4422(26)00169-9
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Endovascular treatment for medium or distal vessel occlusion stroke (DISTAL): 12-month outcomes of a multicentre, open-label, randomised trial

Alex Brehm, Victoria Hellstern, Fee Keil, Nikki Rommers et al.
The Lancet Neurology
Acute Ischemic Stroke Management
article

Endovascular treatment for medium or distal vessel occlusion stroke (DISTAL): 12-month outcomes of a multicentre, open-label, randomised trial

Alex Brehm, Victoria Hellstern, Fee Keil, Nikki Rommers, Daniel Strbian, G. Parrilla, Manuel Bolognese, Alexander von Hessling, Elisabeth Dhondt, Mikel Terceño, Sergio Amaro, Jens Minnerup, Julie Staals, Markus Holtmannspoetter, Mira Katan, Luzia Balmer, C Castaño, Ido van den Wijngaard, Ana Morales, Frans van den Bergh, Adriaan van Es, Jeffrey L Saver, Jo P Peluso, Patrik Michel, Jan-Hendrik Buhk, Isabel Fragata, Silke Wunderlich, Sylvie De Raedt, Juan F Arenillas, Paolo Machi, Götz Thomalla, Andrea Zini, Leonardo Renieri, Volker Puetz, Marios Psychogios, Wim van Zwam, Panagiotis Papanagiotou, Nyika D Kruyt, Ali Khanafer, Johannes Kaesmacher, Steven D Hajdu, Robin Lemmens, Silja Räty, Tomas Dobrocky, Georg Kägi, Flavio Bellante, Angelika Alonso, Daniel P O Kaiser, Urs Fischer, Jens Fiehler, Eike I Piechowiak, Christian Loehr, Christian H. Nolte, Ronen R Leker, Anne Dusart, Mario Martínez-Galdámez, Heinrich P Mattle, Jonathan M Coutinho, Martin Wiesmann, Marc Ribo, Jan S. Kirschke, Federica Rizzo, Jan Gralla
article en

Abstract

BACKGROUND: Long-term evidence for endovascular treatment in medium or distal vessel occlusion stroke is scarce. Three out of four randomised trials reported no benefit of endovascular treatment over best medical treatment at 90 days. We aimed to assess efficacy of endovascular treatment plus best medical treatment versus best medical treatment alone at 12 months in patients enrolled in the DISTAL trial, as well as overall survival. METHODS: DISTAL was an open-label, randomised trial with blinded endpoint assessment conducted at 55 hospitals in Europe and the Middle East. Adults (≥18 years) with acute ischaemic stroke due to medium or distal vessel occlusion (occlusion of co-dominant or non-dominant M2 or M3-M4 middle cerebral artery, A1-A3 anterior cerebral artery, or P1-P3 posterior cerebral artery) presenting from home within 6 h of last known well, or between 6 h and 24 h if neuroimaging demonstrated potentially salvageable tissue, were randomly assigned (1:1) through a centralised web-based system to endovascular treatment plus best medical treatment or best medical treatment alone. The prespecified primary outcome at 12 months was disability measured by use of the ordinal modified Rankin Scale (mRS; scores 5 and 6 combined) in the intention-to-treat population. The only safety outcome was overall survival. The trial is registered on ClinicalTrials.gov (NCT05029414) and is completed. FINDINGS: Between Dec 16, 2021, and July 10, 2024, we enrolled 553 patients. Ten patients declined post-hoc consent, leaving 543 participants in the analysis (239 [44%] females and 304 [56%] males; median age 77 years, IQR 68-84). 271 (50%) were assigned to endovascular treatment plus best medical treatment and 272 (50%) to best medical treatment alone. The median NIHSS score at admission was 6 (IQR 5-9); 355 (65%) participants received intravenous thrombolysis. Predominant occlusion locations were the M2 (239 [44%]), M3 (146 [27%]), P2 (73 [13%]), and P1 (30 [6%]) segments. 12-month data were available for 524 (97%) participants. The median mRS score was 2 (IQR 1-4) in the endovascular treatment plus best medical treatment group and 2 (1-4) in the best medical treatment alone group. There was no difference in 12-month mRS distribution between endovascular treatment plus best medical treatment and best medical treatment alone (adjusted common odds ratio for better functional outcome 0·81, 95% CI 0·59-1·12; p=0·20). Overall survival was similar between the two groups (hazard ratio 1·46, 95% CI 0·93-2·30; p=0·10). INTERPRETATION: In patients with a medium or distal vessel occlusion stroke, endovascular treatment plus best medical treatment was not associated with a reduction of disability or death at 12 months compared with best medical treatment. These results are consistent with the 90-day results. Routine endovascular treatment is therefore not supported for patients with mild-to-moderate medium or distal vessel occlusion stroke. FUNDING: Swiss National Science Foundation, Gottfried und Julia Bangerter-Rhyner-Foundation, Medtronic, Stryker Neurovascular, Phenox, Rapid Medical, and Penumbra.

The Lancet Neurology
Universidad de Valladolid (ES), Goethe University Frankfurt (DE), Leiden University (NL), University of Helsinki (FI), Vrije Universiteit Brussel (BE), Universität Hamburg (DE), University of Lucerne (CH), National and Kapodistrian University of Athens (GR), Heidelberg University (DE), Kantonsspital St. Gallen (CH), Hadassah Medical Center (IL), Leiden University Medical Center (NL), Maastricht University Medical Centre (NL), Helsinki University Hospital (FI), University Hospital of Bern (CH), Ghent University Hospital (BE), University Hospital Heidelberg (DE), University Hospital of Basel (CH), TUM Klinikum (DE), Klinikum Vest (DE), Hospital de São José (PT), Nuremberg Hospital (DE), University Hospital of Geneva (CH), University Medical Center Hamburg-Eppendorf (DE), Hospital Clínic de Barcelona (ES), Azienda Ospedaliero-Universitaria Careggi (IT), Asklepios Klinik St. Georg (DE), Istituto delle Scienze Neurologiche di Bologna (IT), Universitair Ziekenhuis Brussel (BE), Vall d'Hebron Hospital Universitari (ES), University Hospital Frankfurt (DE), Instituto de Biomedicina y Genética Molecular de Valladolid (ES), Hôpital Civil de Charleroi (BE), Hospital Universitario Virgen de la Arrixaca (ES), Amsterdam University Medical Centers (NL), Hospital Universitari Germans Trias i Pujol (ES), Hospital Universitari de Girona Doctor Josep Trueta (ES), University Medical Centre Mannheim (DE), Hospital Clínico Universitario de Valladolid (ES), Klinikum Stuttgart (DE), University Hospital Carl Gustav Carus (DE), Technical University of Munich (DE), Charité - Universitätsmedizin Berlin (DE), University of Amsterdam (NL), RWTH Aachen University (DE), University of Lübeck (DE), University of Lausanne (CH), KU Leuven (BE)
Stryker, Medtronic, Penumbra, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Gottfried und Julia Bangerter-Rhyner-Stiftung
Good health and well-being
Openalex Percentile: Top 8%
Acute Ischemic Stroke Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.